How can cybersecurity protect COVID-19 vaccine supply chains?
In the race to create a #COVID-19 vaccine by collaborating across the industry, pharmaceutical companies have exposed more threat surfaces than existed before the #pandemic.
There’s a proliferation of new threat surfaces cyber attackers are targeting today, as evidenced by threat analysis reports from the U.S. Homeland Security Department’s Cybersecurity & Infrastructure Security Agency (#CISA).
- Prioritize Privileged Access Management (PAM) across the vaccine supply chain, ensuring least privilege access to sensitive data starting with IP.
- Assess every supplier’s security readiness in vaccine supply chains, defining minimum levels of compliance to security standards that include a single, unified security model across all companies.
- Taking a Zero Trust-based approach to secure every endpoint across the vaccine manufacturer’s R&D, Clinical Trials, Manufacturing, and Distribution networks is necessary to shut down cyber attackers taking advantage of legacy security weaknesses approaches.
Read the rest here.